162 related articles for article (PubMed ID: 21099368)
1. A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49.
Liu G; Dou S; Baker S; Akalin A; Cheng D; Chen L; Rusckowski M; Hnatowich DJ
Cancer Biol Ther; 2010 Oct; 10(8):767-74. PubMed ID: 21099368
[TBL] [Abstract][Full Text] [Related]
2. Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector.
Liu G; Dou S; Pretorius PH; Liu X; Chen L; Rusckowski M; Hnatowich DJ
Q J Nucl Med Mol Imaging; 2010 Jun; 54(3):333-40. PubMed ID: 20639818
[TBL] [Abstract][Full Text] [Related]
3. Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice.
Liu G; Dou S; He J; Liu X; Rusckowski M; Hnatowich DJ
Eur J Nucl Med Mol Imaging; 2007 Feb; 34(2):237-46. PubMed ID: 17021815
[TBL] [Abstract][Full Text] [Related]
4. Pretargeting the masses: a means of improving and mainstreaming targeted molecular delivery?
Nguyen V; Conyers JM; Mintz A
Cancer Biol Ther; 2010 Oct; 10(8):775-9. PubMed ID: 20935465
[No Abstract] [Full Text] [Related]
5. Synthesis and in vitro characterization of a dendrimer-MORF conjugate for amplification pretargeting.
Chen X; Dou S; Liu G; Liu X; Wang Y; Chen L; Rusckowski M; Hnatowich DJ
Bioconjug Chem; 2008 Aug; 19(8):1518-25. PubMed ID: 18646837
[TBL] [Abstract][Full Text] [Related]
6. Successful radiotherapy of tumor in pretargeted mice by 188Re-radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analogue.
Liu G; Dou S; Mardirossian G; He J; Zhang S; Liu X; Rusckowski M; Hnatowich DJ
Clin Cancer Res; 2006 Aug; 12(16):4958-64. PubMed ID: 16914585
[TBL] [Abstract][Full Text] [Related]
7. Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake.
Liu G; He J; Dou S; Gupta S; Vanderheyden JL; Rusckowski M; Hnatowich DJ
Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):417-24. PubMed ID: 14691611
[TBL] [Abstract][Full Text] [Related]
8. An improved method for covalently conjugating morpholino oligomers to antitumor antibodies.
He J; Liu G; Dou S; Gupta S; Rusckowski M; Hnatowich D
Bioconjug Chem; 2007; 18(3):983-8. PubMed ID: 17385902
[TBL] [Abstract][Full Text] [Related]
9. Amplification targeting: a modified pretargeting approach with potential for signal amplification-proof of a concept.
He J; Liu G; Gupta S; Zhang Y; Rusckowski M; Hnatowich DJ
J Nucl Med; 2004 Jun; 45(6):1087-95. PubMed ID: 15181145
[TBL] [Abstract][Full Text] [Related]
10. Affinity enhancement pretargeting: synthesis and testing of a 99mTc-labeled bivalent MORF.
He J; Wang Y; Dou S; Liu X; Zhang S; Liu G; Hnatowich D
Mol Pharm; 2010 Aug; 7(4):1118-24. PubMed ID: 20507096
[TBL] [Abstract][Full Text] [Related]
11. Further investigations of morpholino pretargeting in mice--establishing quantitative relations in tumor.
Liu G; He J; Dou S; Gupta S; Rusckowski M; Hnatowich DJ
Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1115-23. PubMed ID: 16133391
[TBL] [Abstract][Full Text] [Related]
12. Tumor pretargeting in mice using (99m)Tc-labeled morpholino, a DNA analog.
Liu G; Mang'era K; Liu N; Gupta S; Rusckowski M; Hnatowich DJ
J Nucl Med; 2002 Mar; 43(3):384-91. PubMed ID: 11884499
[TBL] [Abstract][Full Text] [Related]
13. Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF.
Liu G; Dou S; Pretorius PH; Liu X; Rusckowski M; Hnatowich DJ
Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):272-80. PubMed ID: 17909792
[TBL] [Abstract][Full Text] [Related]
14. An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector.
Liu G; Dou S; Rusckowski M; Hnatowich DJ
Mol Cancer Ther; 2008 May; 7(5):1025-32. PubMed ID: 18483292
[TBL] [Abstract][Full Text] [Related]
15. Investigations of 99mTc morpholino pretargeting in mice.
Liu G; Liu C; Zhang S; He J; Liu N; Gupta S; Rusckowski M; Hnatowich DJ
Nucl Med Commun; 2003 Jun; 24(6):697-705. PubMed ID: 12766607
[TBL] [Abstract][Full Text] [Related]
16. Adding a clearing agent to pretargeting does not lower the tumor accumulation of the effector as predicted.
Liu G; Dou S; Chen X; Chen L; Liu X; Rusckowski M; Hnatowich DJ
Cancer Biother Radiopharm; 2010 Dec; 25(6):757-62. PubMed ID: 21204772
[TBL] [Abstract][Full Text] [Related]
17. 90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy.
Liu G; Dou S; Liu Y; Wang Y; Rusckowski M; Hnatowich DJ
Bioconjug Chem; 2011 Dec; 22(12):2539-45. PubMed ID: 21985267
[TBL] [Abstract][Full Text] [Related]
18. Radiolabeling of MAG3-morpholino oligomers with 188Re at high labeling efficiency and specific radioactivity for tumor pretargeting.
Liu G; Dou S; He J; Yin D; Gupta S; Zhang S; Wang Y; Rusckowski M; Hnatowich DJ
Appl Radiat Isot; 2006 Sep; 64(9):971-8. PubMed ID: 16730997
[TBL] [Abstract][Full Text] [Related]
19. Replacing 99mTc with 111In improves MORF/cMORF pretargeting by reducing intestinal accumulation.
Liu G; Cheng D; Dou S; Chen X; Liang M; Pretorius PH; Rusckowski M; Hnatowich DJ
Mol Imaging Biol; 2009; 11(5):303-7. PubMed ID: 19326173
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal injection is not always a suitable alternative to intravenous injection for radiotherapy.
Dou S; Smith M; Wang Y; Rusckowski M; Liu G
Cancer Biother Radiopharm; 2013 May; 28(4):335-42. PubMed ID: 23469942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
